FGFR2 and cholangiocarcinoma: The ongoing FIGHT-302 study (Phase III, randomized controlled trial; pemigatinib vs. gemcitabine + cisplatin, 2:1 randomization; primary endpoint: PFS) is designed to evaluate the efficacy and safety of pemigatinib as first-line therapy for advanced FGFR2-rearranged cholangiocarcinoma.